Silverback has discontinued the SBT6050 development program. SBT6050 and SBT6290 (HER2-TLR8 and Nectin4-TLR8 ImmunoTAC conjugates for oncology) “We would like to thank the investigators and the staff at each of our sites, and most importantly, the patients who participated in our trial and their families.”
“Upon comprehensive review of our clinical and preclinical data for our TLR8 oncology programs, we have made the decision to discontinue the development of SBT6050 and SBT6290, and focus our resources on SBT8230 for chronic HBV as well as our ImmunoTAC discovery programs,” said Laura Shawver, Ph.D., chief executive officer of Silverback.
#Silverback strategies inc update
(Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended December 31, 2021.
SEATTLE-( BUSINESS WIRE)-Silverback Therapeutics, Inc.
0 kommentar(er)
